Table 2.
Multivariate Cox regression analysis of the CD86/CD163 ratio, clinical factors, and survival in the training and validation cohorts.
| Variable | Recurrence-free Survival | Overall Survival | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Training Cohort (n=310) | ||||
| CD86/CD163 Ratio (high ratio vs. low ratio) | 0.233 (0.123-0.443) | <0.001 | 0.224 (0.111-0.453) | <0.001 |
| Age (≥66 y vs. <66 y) | 0.913 (0.567-1.468) | 0.707 | 1.190 (0.722-1.962) | 0.495 |
| Gender (female vs. male) | 1.113 (0.714-1.736) | 0.637 | 0.992 (0.615-1.598) | 0.972 |
| Mucinous Cancer (yes vs. no) | 1.198 (0.566-2.537) | 0.637 | 1.055 (0.447-2.489) | 0.903 |
| Primary Locations (rectum vs. colon) | 0.827 (0.508-1.348) | 0.446 | 0.700 (0.425-1.153) | 0.161 |
| Tumor Stage (III vs. II) | 2.959 (1.720-5.090) | <0.001 | 3.230 (1.799-5.799) | <0.001 |
| Adjutant Chemotherapy (no vs. yes) | 0.568 (0.325-0.991) | 0.046 | 0.607 (0.343-1.078) | 0.086 |
| Validation Cohort (n=139) | ||||
| CD86/CD163 Ratio (high ratio vs. low ratio) | 0.337 (0.159-0.717) | 0.005 | 0.175 (0.060-0.506) | 0.001 |
| Age (≥66 y vs. <66 y) | 1.971 (0.222-1.159) | 0.107 | 3.404 (1.221-9.488) | 0.019 |
| Gender (female vs. male) | 1.493 (0.775-2.876) | 0.230 | 1.276 (0.605-2.691) | 0.523 |
| Mucinous Cancer (yes vs. no) | 0.359 (0.085-1.507) | 0.161 | 0.507 (0.118-2.176) | 0.361 |
| Primary Locations (rectum vs. colon) | 0.600 (0.262-1.373) | 0.227 | 0.629 (0.237-1.670) | 0.352 |
| Tumor Stage (III vs. II) | 2.914 (1.410-6.020) | 0.004 | 3.153 (1.340-7.418) | 0.009 |
| Adjutant Chemotherapy (no vs. yes) | 1.529 (0.750-3.116) | 0.243 | 1.420 (0.647-3.118) | 0.382 |
HR, hazard ratio; CI, confidence index.